Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × Selective Estrogen Receptor Modulators × Clear all
NCT05079360 2023-03-24

Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

Veru Inc.

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡